0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

New Challenges in the Development of a Conjugate Pneumococcal Vaccine

Robert S. Baltimore, MD
JAMA. 1992;268(23):3366-3367. doi:10.1001/jama.1992.03490230096036.
Text Size: A A A
Published online

Provision of data useful for the development of a conjugate pneumococcal vaccine is the subject of two studies published in this issue of JAMA. Both Eskola et al1 and the Israeli Pediatric Bacteremia and Meningitis Group2 looked at the epidemiology of pneumococcal infections in children to discover the extent of disease, prevalent serotypes, and definition of a high-risk target population of children as preliminary steps in devising a conjugate pneumococcal vaccine strategy. Why is the current vaccine, which has worked well in adults, not used for children, and why go to the trouble of developing a conjugate vaccine?

It has been known for decades that the capsular polysaccharides of Streptococcus pneumoniae confer the antigenic specificity that defines different serotypes and that antibodies to these polysaccharides (also known as soluble-specific substances) are type-specific and protective for human beings. In 1945, MacLeod and associates3 showed that these polysaccharides, used

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();